Evidence map›Paper›PMID 42589287›Full record

ArticleInternational journal of molecular sciences2026

A Novel Mixture Containing

Giulia Valdiserra, Clelia Di Salvo, Letizia Campigli, Vanessa D'Antongiovanni, Carolina Pellegrini, Giada Benedetti, Lara Testai, Cristina Segnani, Laura Benvenuti, Raffaella Coppolecchia and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Giulia ValdiserraUnit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Clelia Di SalvoUnit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.ORCID 0009-0002-7083-4214
Letizia CampigliUnit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.ORCID 0009-0000-9443-9919
Vanessa D'AntongiovanniUnit of Histology and Medical Embryology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-3303-0674
Carolina PellegriniUnit of Histology and Medical Embryology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0003-2644-5430
Giada BenedettiDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.
Lara TestaiDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0003-2431-6248
Cristina SegnaniUnit of Histology and Medical Embryology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Laura BenvenutiUnit of Experimental Biology and Genetics, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0001-6576-5053
Raffaella CoppolecchiaCerbios-Pharma SA, 6917 Lugano, Switzerland.
Nunzia BernardiniUnit of Histology and Medical Embryology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Matteo FornaiUnit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-0812-3959
Luca AntonioliUnit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0003-1241-617X

Funding

Cerbios-Pharma SA No grant number
6 · The paper itself

Abstract

(1) Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain and altered bowel habits, linked to dysbiosis and inflammation. Currently available treatments, focused on symptom management, displayed limited efficacy. Recent research highlights microbiota modulation as a potential therapeutic strategy to restore intestinal barrier integrity; (2) A dextran sulfate sodium (DSS)-induced mouse model of post-colitis IBS-like symptoms was performed to evaluate the effect of a novel mixture of

Indexed as

ColitisEnterococcusIrritable Bowel SyndromeProbioticsAnimalsButyratesDextran SulfateDisease Models, AnimalFolic AcidIntestinal Barrier FunctionIntestinal MucosaMaleMiceMitochondriaButyratesDextran SulfateFolic AcidbutyrateEnterococcus lactis SF68®gutinflammationirritable bowel syndromeprobiotics

Identifiers

PMID42589287
PMCPMC13467298

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.